SOSTDC1 was methylated in 95.5% (193/202) of invasive BC patients and 75% (12/16) of DCIS patients, while it was unmethylated in 83.7% (31/37) benign patients and (202/203) in 99.5% of healthy controls. Here, SOSTDC1 is linked to breast cancer.